BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, July 13, 2026
Home » Topics » Medical technology

Medical technology
Medical technology RSS Feed RSS

Patent Watch: Sanuwave receives patent for sterilization with shock waves

May 13, 2014

World in Review: Foundation Medicine obtains CE mark for FoundationOne

May 13, 2014

Products

May 13, 2014

Cyberonics gains positive results from PuLsE post approval study

May 13, 2014
By Omar Ford

Deals: Allergan says Valeant proposal not in best interest of company

May 13, 2014

Financings: InVivo Therapeutics closes underwritten public offering

May 13, 2014

Coverage frontiers; the ICD consensus statement

May 12, 2014
By Mark McCarty
The 2014 scientific sessions hosted by the Heart Rhythm Society are over, and there was a lot of news coming out of San Francisco. One of the items that caught my eye was a consensus statement by HRS and a couple of other physician societies about appropriate use of implantable cardioverter defibrillators for populations not well represented in clinical trials. The first question that occurs to the casual observer is; how seriously will government take this consensus standard? The background for this is in part the...
Read More

MDD's Neurology Extra

May 12, 2014
By Robert Kimball

Heart Rhythm Society 2014: Hopkins team forging ahead with MRI as mapping tool for ablation

May 12, 2014
By Mark McCarty
SAN FRANCISCO — This year's edition of the Heart Rhythm Society (HRS; Washington) scientific sessions included a presentation by Natalia Trayanova, PhD, of Johns Hopkins (Baltimore), who is spearheading an effort at the Hopkins computational cardiology lab to come up with a model for a virtual electrophysiology lab. She said this current effort is built around "an MRI-based modeling environment," with the objective being the acquisition of data from the level of molecules to aid in the diagnosis and treatment of heart disease for each individual patient based on that patient's specific features.
Read More

Heart Rhythm Society 2014: Cardiologists debate whether ablation overused to treat afib

May 12, 2014
By Mark McCarty
Previous 1 2 … 3248 3249 3250 3251 3252 3253 3254 3255 3256 … 10253 10254 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 10, 2026.
  • Wainua autoinjector

    Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy

    BioWorld
    News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
  • Silhouette with keyhole

    FENS 2026: Next-gen biologics take on brain disease

    BioWorld
    Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
  • Modius Spero wearable neuromodulation device

    Neurovalens granted FDA approval for PTSD therapy for US veterans

    BioWorld
    Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
  • NRF2 activators reported in Vailima Peninsula patent

    BioWorld Science
    Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing